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Abstract
PURPOSE
To determine the differences in enhancement pattern of hepatocellular carcinoma (HCC) during first 5 minutes of post-contrast phases MRI with gadoxetic acid (Gd-EOB-DTPA) versus gadobenate dimeglumine (Gd-BOPTA) using the FDA approved doses.
METHODS AND MATERIALS
95 patients with HCC were examined on 1.5 T scanner; 74 patients with Gd-BOPTA and 21 with Gd-EOB-DTPA. Using the same MRI parameters, post-contrast imaging was performed at pre-contrast, arterial, portal venous, equilibrium, and 5 minute delayed phases. Gd-EOB-DTPA was administered at a dose of 0.025 mmol/kg body weight and Gd-BOPTA at a dose of 0.1 mmol/kg body weight. Both agents were injected at rate of 2 mL/sec and arterial phase was timed by using bolus-triggering software. The contrast-tonoise ratio (CNR) was calculated by (SI lesion -SI liver )/SD background . (SD=Standard Deviation, SI=signal intensity)
RESULTS
Mean CNRs were not statistically significant different in arterial (p=0.3), portal venous (p=0.1) and 5 minute delayed phases (p=0.73). CNR of lesions scanned with Gd-EOB-DTPA was significantly higher in the equilibrium phase (p=0.006). When pooling the data from all for post-contrast phases, HCCs demonstrated no significant change in enhancement pattern with Gd-EOB-DTPA compared to Gd-BOPTA. CNRs of lesions 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Page | 3 scanned with Gd-EOB-DTPA were lower in arterial phase compared to Gd-BOPTA, though this did not reach statistical significance.
CONCLUSION
Gd-EOB-DTPA in HCC imaging resulted in lower CNR during the arterial phase and higher CNR during the portal venous, equilibrium and 5 minute delayed phases compared to Gd-BOPTA using the FDA approved doses, however overall there was no statistical significance (P=0.077).
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Keywords: Hepatocellular carcinoma, MRI, contrast, Gadoxetate Disodium, Gadobenate Dimeglumine   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61 Introduction Gadoxetate Isodium (Gd-EOB-DTPA, Eovist/Primovist®, Bayer) was approved by the FDA for clinical use in 2008 and has emerged as a valuable hepatobiliary phase MRI contrast agent [1, 2] . The presence or absence of contrast enhancement in the hepatobiliary phase can be very useful in differentiating previously indeterminate hepatic lesions, such as focal nodular hyperplasia, well-differentiated hepatocellular carcinoma (HCC), adenomas, atypical hemangiomas, and metastases [2] [3] [4] .
Approximately 50% of Gd-EOB-DTPA undergoes hepatobiliary excretion and 50% is excreted by the kidneys [2] . After being taken up by hepatocytes via the organic anion transport protein, Gd-EOB-DTPA redistributes to the extracellular space and undergoes delayed excretion into bile ducts or sinusoids [5] . Extracellular space redistribution and gradual hepatobiliary phase excretion allows for prolonged dynamic imaging and a progressive increase in enhancement of hepatocytes and hepatocyte-containing lesions.
When hepatocellular dysfunction is present, as a result of advanced cirrhosis, Gd-EOB-DTPA is increasingly excreted via the alternate renal pathway [6] , which may reduce visibility of lesions on the hepatobiliary phase images. In comparison, Gadobenate dimeglumine (Gd-BOPTA) undergoes 78-96% renal excretion and therefore yields a lower percentage of hepatocyte enhancement in the hepatobiliary phase when compared to Gd-EOB-DTPA [7] . Page | 6
In practical terms, the hepatobiliary phase of scans performed with Gd-EOB-DTPA often provides valuable diagnostic information; for example, most HCC's and almost all metastatic lesions do not take up the agent, and will therefore appear as low signal focal lesions on 20-minute delayed hepatobiliary phase images [2] .
There is, however, a possible disadvantage of Gd-EOB-DTPA. Gd-EOB-DTPA is distributed at a molar concentration less than half that of most other agents, including Gd-BOPTA, and the label instructions recommends a lower milliliter dose (Table 1) . Thus, the total number of moles of agent is usually 25% of a typical scan performed with Gd-BOPTA. Since arterial phase wash-in and delayed phase relative wash-out are hallmarks of HCC diagnosis, this can be an issue in interpreting Gd-EOB-DTPA enhanced MR scans. For this reason, we investigated and compared the enhancement of HCC with Gd-EOB-DTPA to that of Gd-BOPTA within the first 5 minutes of contrast injection.
Materials and Methods
Following FDA approval of Gd-EOB-DTPA in 2008, our institution, a major academic tertiary care center with a large liver transplant service, started using Gd-EOB-DTPA for screening and follow up of HCC in all liver MR exams over a period of 9 months.
Patients had chronic liver disease and were scanned on 1.5 T MR scanners (Magnetom Avanto, Siemens Medical Solutions, Malvern, PA USA). Following approval from the institutional review board, a HIPPA compliant retrospective study was performed. Data collection was performed in patients with known HCC that were scanned during this 9- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 month time period with Gd-EOB-DTPA (n=21 patients) and from prior cases of known HCC scanned with Gd-BOPTA (n=78).
In both groups, same imaging parameters were used to acquire contrast-enhanced phases using a 3D fat-suppressed, T1-weighted volume interpolated gradient echo sequence The degree of enhancement of liver lesions was quantified by drawing a circular region of interest (ROI) within the lesion margin (SI lesion ) and around normal liver parenchyma (SI liver ). The sensitivity of HCC detection with Gd-EOB-DTPA is decreased in lesions less than 10 mm in diameter [8] ; therefore minimum ROI was set at 1 cm 2 . The standard deviation of background noise was calculated by drawing an ROI outside of the patient (SD background ) on the same image. The contrast-to-noise ratio (CNR) was calculated using the equation: CNR = (SI lesion -SI liver ) / SD background . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Page | 8
Statistical Analysis
The Mixed-Effect Repeat Measure (MMRM) model with unstructured variancecovariance matrix was used to model the repeated CNR including time, group (Gd-BOPTA or Gd-EOB-DTPA), and the interaction between time and group as fixed effects.
The F tests were used to examine the overall difference between the two groups and the difference in mean CNR between the Gd-EOB-DTPA and Gd-BOPTA group at each time point.
Results
Mean CNRs after administration of Gd-EOB-DTPA and Gd-BOPTA are shown on Figure 1 and Table 2 . In the post contrast arterial phase, the mean CNR was 9.7 (±49) in the Gd-EOB-DTPA group and 19 (±36) in the Gd-BOPTA group. In the portal venous phase, the mean CNR was -15.2 (±38) in the Gd-EOB-DTPA group and 4.3 (±55) in the Gd-BOPTA group. In the equilibrium phase, the mean CNR was -25 (±34) in the Gd-EOB-DTPA group and -2.9 (±28) in the gadobenate group. In the 5 minute delayed phase, the mean CNR was -31.4 (±45) in the Gd-EOB-DTPA group and -27.7 (±35) in the Gd-BOPTA group.
The overall difference in CNRs when including all time points did not reach statistical significance (P=0.077). There was greater arterial enhancement on the arterial phase images with Gd-BOPTA than with Gd-EOB-DTPA, but this did not reach statistical significance. However, the contrast reverses on later vascular phase images; lesions are usually hypointense compared to liver on later vascular phases with both agents, a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 phenomenon termed "washout" and indicated by negative CNR values. Our data showed greater CNRs and seemingly greater lesion "washout" relative to liver on the later vascular phases on the Gd-EOB-DTPA images compared to the Gd-BOPTA. This difference may be because of progressive enhancement of the liver with Gd-EOB-DTPA, likely due to the combined effects of vascular perfusion and hepatocyte uptake of the contrast agent (Figure 2 ). Negative CNRs observed beginning with portal venous phase using Gd-EOB-DTPA, compared to equilibrium phase with the Gd-BOPTA.
Discussion
When compared to Gd-BOPTA, at standard doses Gd-EOB-DTPA demonstrates lower enhancement in normal vasculature and solid abdominal organs [9] and lower dynamic enhancement of the liver vasculature [10] . Frydrychowicz et al compared dynamic post contrast hepatic vasculature signal to noise ratio (SNR) with the higher (non-FDA approved) Gd-EOB-DTPA dose of 0.05 mmol/kg to the standard dose of Gd-BOPTA.
Hepatic vascular SNR was lower in the Gd-EOB-DTPA group despite doubling the FDAapproved dose, and it was suggested that this agent be reserved for cases in which hepatobiliary phase imaging is needed [7] . Therefore, it should not be surprising that a hypervascular lesion such as HCC should show relatively lower early dynamic enhancement with Gd-EOB-DTPA compared to Gd-BOPTA.
The sentinel paper by Vogl et al comparing the contrast enhancement in liver tumors with
Gd-EOB-DTPA versus Gd-BOPTA was published in 1996 [11] . Patients with a variety 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Our current study has the advantage of a much larger sample size of HCC lesions in the Gd-EOB-DTPA group (n=21) and Gd-BOPTA group (n=74), versus a total sample size of 12 in the 1996 study. However, our study involved retrospective analysis of HCC lesions in different patients, while the 1996 study evaluated known lesions in the same patient with both contrast agents. The relatively small, disproportionate sample size of patients in the Gd-EOB-DTPA group (n=21) may have limited statistical analysis.
The preponderance of evidence in our study and in the literature suggests that Gd-EOB-DTPA offers relatively lower CNR in the liver vasculature, parenchyma, and hepatocellular carcinomas during the first 5 minutes of dynamic imaging when compared to Gd-BOPTA. Given the identical imaging parameters, decreased arterial phase CNRs in the Gd-EOB-DTPA group in our study is probably secondary to using the lower FDA approved and manufacturer recommended dose of Gd-EOB-DTPA (0.025 mmol/kg) which is 25% of the dose administered by Gd-BOPTA (0.1 mmol/kg). Our clinical experiences combined with relatively higher cost of Gd-EOB-DTPA have led our institution to stop using the use of Gd-EOB-DTPA for screening of HCC in suspected patients. It remains a useful agent for problem solving in cirrhotic patients, and other 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Page | 12 lesions such as metastasis, for which the lower arterial phase enhancement may be less of an issue, and for whom the hepatobiliary phase images may be especially efficacious.
Conclusion
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